Alland Leila 4

What Happened Leila Alland, a director of Abeona Therapeutics, reported an open-market/private sale of 18,065 shares on 2026-02-02. The weighted-average price reported was $5.09, with proceeds of approximately $91,962. The filing states the sale was made to cover tax obligations associated with the vesting of restricted stock awards.

Key Details

• Transaction date: 2026-02-02
• Transaction type/code: Sale (S) — reported as open market or private sale
• Shares sold: 18,065
• Price: weighted average $5.09; reported range $5.09–$5.12 (sold in multiple transactions) (Footnote F2)
• Proceeds: ~$91,962
• Purpose: To cover tax withholding on vested restricted stock awards (Footnote F1)
• Shares owned after transaction: Not specified in this Form 4 filing
• Filing timeliness: Reported same day (no late filing indicated)

Context This sale was reported as a tax-related transaction tied to the vesting of restricted stock rather than a discretionary investment decision. Such sales to satisfy tax obligations are common and do not necessarily reflect the insider's view on the company’s prospects. The filer has offered to provide details of the number of shares sold at each price within the reported range upon request (per Footnote F2).